title: Reduction in thyroid perfusion after bevacizumab treatment.
authors.affiliation: 1 Department of Internal Medicine, VU University Medical Center , Amsterdam, The Netherlands .
authors.forename: Astrid A M
authors.initials: AA
authors.lastname: van der Veldt
authors.forename: Adriaan A
authors.initials: AA
authors.lastname: Lammertsma
authors.forename: Egbert F
authors.initials: EF
authors.lastname: Smit
mesh_terms: D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011758:Pyrroles / Q000009:adverse effects*; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D017479:Receptors, Platelet-Derived Growth Factor / Q000037:antagonists & inhibitors*; D013959:Thyroid Diseases / Q000139:chemically induced*; D040281:Vascular Endothelial Growth Factor Receptor-1 / Q000037:antagonists & inhibitors*; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000037:antagonists & inhibitors*
chemical_list: D007211:Indoles; D047428:Protein Kinase Inhibitors; D011758:Pyrroles; D020794:Receptor Protein-Tyrosine Kinases; D017479:Receptors, Platelet-Derived Growth Factor; D040281:Vascular Endothelial Growth Factor Receptor-1; D040301:Vascular Endothelial Growth Factor Receptor-2